Krystal Biotech beats Q1 estimates as VYJUVEK revenue growth, pipeline progress, and cash strength support results.
Stock Earnings Results
May 4, 2026
Table of Contents
May 4, 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) reported first-quarter 2026 results above expectations, supported by continued VYJUVEK revenue growth, pipeline progress, and a strong cash position.
Krystal Biotech is a biotechnology company developing genetic medicines, including treatments for dystrophic epidermolysis bullosa and other rare diseases.
The company reported EPS of $1.83, above estimates of $1.45, representing a 26.2% earnings surprise and 31.9% revenue growth. Revenue came in at $116.36 million, above estimates of $112.15 million.
Krystal reported $116.4 million in first-quarter VYJUVEK global revenue, up 32% from the prior-year period. Since launch, VYJUVEK has generated $846.7 million in revenue.
The company also reported a 95% gross margin for the quarter, reinforcing the profitability of its commercial product base.
In the U.S., Krystal has secured more than 695 reimbursement approvals for VYJUVEK.
The company added more than 60 new prescribers in the first quarter and has reached more than 570 unique prescribers since launch, showing continued expansion of its commercial footprint.
Krystal completed enrollment in its KB803 registrational study for corneal abrasions in DEB patients.
The company expects top-line results from KB803 in the fourth quarter of 2026 and remains on track for KB803 and KB801 registrational data readouts this year.
The FDA granted platform technology designation for KB407 in cystic fibrosis and KB111 in Hailey-Hailey disease.
This matters because platform designation could help streamline future regulatory development across related programs if the company continues building supportive data.
Investors are likely to watch whether Krystal can sustain VYJUVEK growth while advancing new indications and pipeline programs.
The key areas are:
Krystal’s quarter shows how biotech earnings can become more powerful when commercial execution and pipeline milestones line up.
The earnings beat was supported by VYJUVEK growth, but the longer-term story depends on whether Krystal can turn its genetic medicine platform into multiple approved products.
Platforms like LevelFields track earnings results, FDA approvals, layoffs, activist investor stake, and more helping investors identify when biotech earnings include both growth catalysts and profitability risks.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better investor.
AI scans for events proven to impact stock prices, so you don't have to.
LEARN MORE